Dualitas Therapeutics
Dualitas Therapeutics Appoints Karim Dabbagh Chief Executive Officer
Dualitas Therapeutics announced a leadership change on June 8, 2026. Dualitas Therapeutics appointed Karim Dabbagh, formerly President and CEO of Silver Creek Pharmaceuticals, as Chief Executive Officer, with former interim CEO Rich Murray remaining on the Board of Directors.
What changed
Karim Dabbagh was named Chief Executive Officer. Rich Murray, who served as interim CEO from January 2025, will remain on the Board of Directors.
- Leader: Karim Dabbagh
- Role: Chief Executive Officer
- Effective: Not specified in the announcement
- Announcement date: June 8, 2026
Leadership background
Dabbagh was previously President and CEO of Silver Creek Pharmaceuticals and has more than two decades of biotech and pharma leadership experience, specializing in immunology and inflammation. He also served as President and CEO of Second Genome, where he helped build the company’s R&D platform and secured collaborations with Gilead Sciences and Bayer. He previously led Pfizer’s immunoregulation department and held leadership roles in Inflammation Discovery Research at Roche.
The mandate
Dualitas said Dabbagh will lead the company as it advances its lead development candidate, DTX-102, for autoimmune indications including rheumatoid arthritis. The company said IND-enabling studies have begun for DTX-102 and that it is anticipated to enter the clinic in 2027.
Why this matters for GTM teams
Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.
Source and methodology
This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.
Primary source: Dualitas Therapeutics leadership announcement.
Related Reports
Asembia Appoints David Skomo Chief Executive Officer
Asembia appointed David Skomo as CEO, succeeding co-founder Lawrence Irene, and said he will focus on strengthening the company’s commercial capabilities, technology platform, and pharmacy services.
Lassila and Tikanoja Appoints Ari-Pekka Määttänen President and CEO
Lassila and Tikanoja appointed Ari-Pekka Määttänen, CEO of Fintoil Oy, as President and CEO from May 1, 2027, succeeding Eero Hautaniemi to lead the circular economy company’s next phase of growth.
Sciensus Appoints James Tugendhat Chief Executive Officer
Sciensus has appointed James Tugendhat OBE, most recently Group CEO of HC-One, as Chief Executive Officer, taking over from interim CEO Gordon Cox.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


